FR2798857B1 - Utilisation d'une proteine de membrane ompa d'enterobacterie associee a un peptide immunogene du vrs pour la preparation de vaccins administrables par voie nasale - Google Patents

Utilisation d'une proteine de membrane ompa d'enterobacterie associee a un peptide immunogene du vrs pour la preparation de vaccins administrables par voie nasale

Info

Publication number
FR2798857B1
FR2798857B1 FR9911888A FR9911888A FR2798857B1 FR 2798857 B1 FR2798857 B1 FR 2798857B1 FR 9911888 A FR9911888 A FR 9911888A FR 9911888 A FR9911888 A FR 9911888A FR 2798857 B1 FR2798857 B1 FR 2798857B1
Authority
FR
France
Prior art keywords
enterobacteria
vaccines
administrative
nasal
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9911888A
Other languages
English (en)
Other versions
FR2798857A1 (fr
Inventor
Nathalie Corvaia
Liliane Goestch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9911888A priority Critical patent/FR2798857B1/fr
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to CN00814283A priority patent/CN1379682A/zh
Priority to MXPA02003132A priority patent/MXPA02003132A/es
Priority to AU75301/00A priority patent/AU7530100A/en
Priority to JP2001524627A priority patent/JP2003528812A/ja
Priority to CA002385404A priority patent/CA2385404A1/fr
Priority to BR0014246-8A priority patent/BR0014246A/pt
Priority to EP00964347A priority patent/EP1218029A1/fr
Priority to PCT/FR2000/002626 priority patent/WO2001021203A1/fr
Publication of FR2798857A1 publication Critical patent/FR2798857A1/fr
Priority to ZA200202175A priority patent/ZA200202175B/xx
Application granted granted Critical
Publication of FR2798857B1 publication Critical patent/FR2798857B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
FR9911888A 1999-09-23 1999-09-23 Utilisation d'une proteine de membrane ompa d'enterobacterie associee a un peptide immunogene du vrs pour la preparation de vaccins administrables par voie nasale Expired - Fee Related FR2798857B1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
FR9911888A FR2798857B1 (fr) 1999-09-23 1999-09-23 Utilisation d'une proteine de membrane ompa d'enterobacterie associee a un peptide immunogene du vrs pour la preparation de vaccins administrables par voie nasale
PCT/FR2000/002626 WO2001021203A1 (fr) 1999-09-23 2000-09-22 Utilisation d'une proteine de membrane ompa d'enterobacterie associee a un peptide immunogene du vrs pour la preparation de vaccins administrables par voie nasale
AU75301/00A AU7530100A (en) 1999-09-23 2000-09-22 Use of an outer membrane protein a of an enterobacterium associated with a rsv immunogenic peptide for preparing vaccines for intranasal administration
JP2001524627A JP2003528812A (ja) 1999-09-23 2000-09-22 Ｒｓｖの免疫原性ペプチドと組み合わせた腸内細菌ｏｍｐａ膜タンパク質の経鼻投与可能なワクチンの製造のための使用
CA002385404A CA2385404A1 (fr) 1999-09-23 2000-09-22 Utilisation d'une proteine de membrane ompa d'enterobacterie associee a un peptide immunogene du vrs pour la preparation de vaccins administrables par voie nasale
BR0014246-8A BR0014246A (pt) 1999-09-23 2000-09-22 Utilização de uma proteìna ompa de enterobactéria, ou um de seus fragmentos, associada a um peptìdeo imunogênico derivado do vìrus respiratório sincicial
CN00814283A CN1379682A (zh) 1999-09-23 2000-09-22 与rsv的致免疫肽结合的肠杆菌外膜蛋白a在制备经鼻内给药的疫苗中的用途
MXPA02003132A MXPA02003132A (es) 1999-09-23 2000-09-22 Uso de una proteina a de membrana externa (ompa) de enterobacteria combinada con un peptido inmunogenico rsv para preparar vacunas para administracion intranasal.
EP00964347A EP1218029A1 (fr) 1999-09-23 2000-09-22 Utilisation d'une proteine de membrane ompa d'enterobacterie associee a un peptide immunogene du vrs pour la preparation de vaccins administrables par voie nasale
ZA200202175A ZA200202175B (en) 1999-09-23 2002-03-18 Use of an outer membrane protien a of an enterobacterium associated with a RSV immunogenic peptide for preparing vaccines for intranasal administration.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9911888A FR2798857B1 (fr) 1999-09-23 1999-09-23 Utilisation d'une proteine de membrane ompa d'enterobacterie associee a un peptide immunogene du vrs pour la preparation de vaccins administrables par voie nasale

Publications (2)

Publication Number Publication Date
FR2798857A1 FR2798857A1 (fr) 2001-03-30
FR2798857B1 true FR2798857B1 (fr) 2003-06-06

Family

ID=9550162

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9911888A Expired - Fee Related FR2798857B1 (fr) 1999-09-23 1999-09-23 Utilisation d'une proteine de membrane ompa d'enterobacterie associee a un peptide immunogene du vrs pour la preparation de vaccins administrables par voie nasale

Country Status (10)

Country Link
EP (1) EP1218029A1 (fr)
JP (1) JP2003528812A (fr)
CN (1) CN1379682A (fr)
AU (1) AU7530100A (fr)
BR (1) BR0014246A (fr)
CA (1) CA2385404A1 (fr)
FR (1) FR2798857B1 (fr)
MX (1) MXPA02003132A (fr)
WO (1) WO2001021203A1 (fr)
ZA (1) ZA200202175B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2827605B1 (fr) * 2001-07-20 2004-07-16 Pf Medicament Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
FR2828106A1 (fr) * 2001-08-02 2003-02-07 Pf Medicament Utilisation d'une omp d'enterobacterie de faible masse moleculaire comme porteur et/ou adjuvant
CA2594334A1 (fr) * 2005-01-07 2006-07-13 Alnylam Pharmaceuticals, Inc. Modulation d'arn interferent du virus respiratoire syncytial et utilisations therapeutiques de cette modulation
KR101425404B1 (ko) * 2009-07-17 2014-08-01 한림대학교 산학협력단 리포좀에 포집된 올리고뉴클레오타이드 및 에피토프를 포함하는 면역증강용 조성물
EA201891945A3 (ru) 2012-08-01 2019-05-31 Бавариан Нордик А/С Вакцина рекомбинантного модифицированного вируса осповакцины анкара (mva) респираторно-синцитиального вируса (rsv)
CN103243112A (zh) * 2013-05-16 2013-08-14 河北科星药业有限公司 预防大肠杆菌病的基因tsh-Ser及其制备以及利用其编码的蛋白

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1331355C (fr) * 1986-04-21 1994-08-09 Bioenterprises Pty. Ltd Immunopotentialisation
FR2726577B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Procede d'obtention d'un peptide derive du virus respiratoire syncitial, polypeptide et bacterie l'exprimant, et leurs applications a titre de medicament
FR2726472B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Proteine porteuse a effet adjuvant, complexe immunogene la contenant, leur procede de preparation, sequence nucleotidique et vaccin
FR2766192B1 (fr) * 1997-07-17 2001-07-13 Pf Medicament Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie
CN1174099C (zh) * 1997-07-18 2004-11-03 康诺特实验室有限公司 编码呼吸道合胞病毒的g蛋白的核酸疫苗
FR2776521B1 (fr) * 1998-03-27 2000-12-15 Pf Medicament Utilisation de conjugues p40 actifs par voie nasale

Also Published As

Publication number Publication date
MXPA02003132A (es) 2002-09-30
CA2385404A1 (fr) 2001-03-29
BR0014246A (pt) 2002-05-21
EP1218029A1 (fr) 2002-07-03
CN1379682A (zh) 2002-11-13
JP2003528812A (ja) 2003-09-30
FR2798857A1 (fr) 2001-03-30
WO2001021203A1 (fr) 2001-03-29
WO2001021203A9 (fr) 2002-05-10
ZA200202175B (en) 2002-12-24
AU7530100A (en) 2001-04-24

Similar Documents

Publication Publication Date Title
DE69837924D1 (de) Chromophoren zur herstellung von neuen tandem-konjugaten
LU91306I2 (fr) Mitratapide, optionnellement sous forme d'un sel d'addition acide pharmaceutiquement acceptable (YARVITAN)
DZ3358A1 (fr) Formulations en solution pharmaceutiques pour inhalateurs-doseurs sous pression
DK1210113T3 (da) Kombinerede vaccinepræparater
LU91442I2 (fr) "Varénicline, optionnellement sous forme d'un sel pharmaceutiquement acceptable, y compris le sel tartrate"
WO2002072011A3 (fr) Agents therapeutiques et d'imagerie stabilises
FR2734483B1 (fr) Forme d'administration pharmaceutique comprenant de l'oxybutynine
DE60040727D1 (de) Menschliche papillomavirus impfstoff-formulierungen
NZ503830A (en) Papilloma virus capsomere vaccine formulations and methods of use
DE60235719D1 (de) Frauenhygieneartikel zur verabreichung von arzneimittel
NO20013736L (no) Pyrazolkarboksylsyrederivater, deres fremstilling og farmasöytiske preparater inneholdende de samme
ATE265852T1 (de) Geschmackskaschierte flüssige arzneizubereitungen
PL353321A1 (en) Hydrodynamically balancing oral drug delivery system
NO20020304L (no) Konserverte farmasoytiske preparater
EP2452684A3 (fr) Micelles
NO20025277L (no) Farmasoytisk administreringsform for peptider, dens fremstilling samt anvendelse
DE69531793D1 (de) Immunogene zubereitungen
FR2798857B1 (fr) Utilisation d'une proteine de membrane ompa d'enterobacterie associee a un peptide immunogene du vrs pour la preparation de vaccins administrables par voie nasale
HUP0200841A2 (en) Anti-hiv 1 vaccine comprising the entire or part of the tat hiv-1 protein
FR2819810B1 (fr) Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin
WO2000052045A3 (fr) Peptides immunogenes derives de mage-3 presentes par le complexe majeur d'histocompatibilte (mch) de categorie ii et utilisations associees
HK1042092A1 (en) Novel morpholine derivatives, method for the prod uction thereof and pharmaceutical preparations containing said derivatives.
ZA200300777B (en) Process for the preparation of peptide salts, their use and pharmaceutical preparations comprising the peptide salts.
FR2778566B1 (fr) Preparations pectiques utilisables comme support de medicament
RU2001127052A (ru) Штамм вируса Эбола "Заир Ч-15" для проведения модельных экспериментов и приготовления диагностических и вакцинных препаратов

Legal Events

Date Code Title Description
ST Notification of lapse
RN Application for restoration
D3 Decision to revoke the decision of lapse
ST Notification of lapse